# Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma

> **NCT01495988** · PHASE2 · TERMINATED · sponsor: **Melanoma Research Foundation Breakthrough Consortium** · enrollment: 10 (actual)

## Conditions studied

- Melanoma
- Metastatic Melanoma

## Interventions

- **DRUG:** Vemurafenib
- **DRUG:** Bevacizumab
- **DRUG:** Cobimetinib

## Key facts

- **NCT ID:** NCT01495988
- **Lead sponsor:** Melanoma Research Foundation Breakthrough Consortium
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-08
- **Primary completion:** 2016-01
- **Final completion:** 2016-06
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Slow accrual; toxicity; change in priorities
- **Last updated:** 2017-10-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01495988

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01495988, "Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT01495988. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*